Literature DB >> 29951799

Atrioventricular valve disease: challenges and achievements in percutaneous treatment.

Roman Pfister1, Stephan Baldus2.   

Abstract

Percutaneous treatment of atrioventricular (AV) valve disease has long been restricted to therapy of mitral stenosis, and was only lately expanded to mitral regurgitation. 15 years ago the MitraClip edge to edge repair was first applied to human pathology. In Europe, German centers were the first to widely adopt this technique in patients with mitral regurgitation and high or inappropriate risk for surgery. Given the exponential rise in implantation procedures, expertise of the operators and investigator initiated investigations substantially contributed to improvements in procedural processes and patient selection. Meanwhile, additional techniques to repair the mitral and tricuspid valve were introduced to German interventionalists, both reconstructive techniques as well as first experiences with transcatheter implantation of mitral valve bioprostheses. Of note, specialized Heart Valve referral Centers catalyzed the adoption of these techniques. This review summarizes the contributions of German Heart Centers to recent developments in percutaneous therapy of AV valve disease.

Entities:  

Keywords:  MitraClip; Mitral regurgitation; Percutaneous valve treatment; Tricuspid regurgitation

Mesh:

Year:  2018        PMID: 29951799     DOI: 10.1007/s00392-018-1303-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  44 in total

1.  Response to Prof. Dr. med. Gunther Wiesner, Prof. Dr. med. Peter Tassani-Prell, and Dr. Patrick Mayr : Deep sedation versus general anaesthesia in percutaneous edge-to-edge mitral valve reconstruction using the MitraClip system.

Authors:  Suzanne de Waha; Steffen Desch; Ingo Eitel; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2017-02       Impact factor: 5.460

2.  MitraClip therapy in surgical high-risk patients: identification of echocardiographic variables affecting acute procedural outcome.

Authors:  Edith Lubos; Michael Schlüter; Eik Vettorazzi; Britta Goldmann; Daniel Lubs; Johannes Schirmer; Hendrik Treede; Hermann Reichenspurner; Stefan Blankenberg; Stephan Baldus; Volker Rudolph
Journal:  JACC Cardiovasc Interv       Date:  2014-03-14       Impact factor: 11.195

3.  Clinical outcome of critically ill, not fully recompensated, patients undergoing MitraClip therapy.

Authors:  Volker Rudolph; Michael Huntgeburth; Ralph Stephan von Bardeleben; Peter Boekstegers; Edith Lubos; Wolfgang Schillinger; Taoufik Ouarrak; Holger Eggebrecht; Christian Butter; Björn Plicht; Andreas May; Olaf Franzen; Joachim Schofer; Jochen Senges; Stephan Baldus
Journal:  Eur J Heart Fail       Date:  2014-10-15       Impact factor: 15.534

4.  Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction.

Authors:  Olaf Franzen; Stephan Baldus; Volker Rudolph; Sven Meyer; Malgorzata Knap; Dietmar Koschyk; Hendrik Treede; Achim Barmeyer; Joachim Schofer; Angelika Costard-Jäckle; Michael Schlüter; Hermann Reichenspurner; Thomas Meinertz
Journal:  Eur Heart J       Date:  2010-03-10       Impact factor: 29.983

5.  Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure.

Authors:  Mathias Orban; Christian Besler; Daniel Braun; Michael Nabauer; Marion Zimmer; Martin Orban; Thilo Noack; Julinda Mehilli; Christian Hagl; Joerg Seeburger; Michael Borger; Axel Linke; Holger Thiele; Steffen Massberg; Joerg Ender; Philipp Lurz; Jörg Hausleiter
Journal:  Eur J Heart Fail       Date:  2018-04-26       Impact factor: 15.534

6.  Elevated Mitral Valve Pressure Gradient After MitraClip Implantation Deteriorates Long-Term Outcome in Patients With Severe Mitral Regurgitation and Severe Heart Failure.

Authors:  Michael Neuss; Thomas Schau; Akihiro Isotani; Markus Pilz; Maren Schöpp; Christian Butter
Journal:  JACC Cardiovasc Interv       Date:  2017-05-08       Impact factor: 11.195

7.  MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry.

Authors:  Stephan Baldus; Wolfgang Schillinger; Olaf Franzen; Raffi Bekeredjian; Horst Sievert; Joachim Schofer; Karl-Heinz Kuck; Thomas Konorza; Helge Möllmann; Christoph Hehrlein; Taoufik Ouarrak; Jochen Senges; Thomas Meinertz
Journal:  Eur J Heart Fail       Date:  2012-06-08       Impact factor: 15.534

8.  Treatment of Chronic Functional Mitral Valve Regurgitation With a Percutaneous Annuloplasty System.

Authors:  Georg Nickenig; Robert Schueler; Antonio Dager; Pedro Martinez Clark; Alexandre Abizaid; Tomasz Siminiak; Pawel Buszman; Marcin Demkow; Adrian Ebner; Federico M Asch; Christoph Hammerstingl
Journal:  J Am Coll Cardiol       Date:  2016-06-28       Impact factor: 24.094

9.  Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial.

Authors:  Francesco Maisano; Maurizio Taramasso; Georg Nickenig; Christoph Hammerstingl; Alec Vahanian; David Messika-Zeitoun; Stephan Baldus; Michael Huntgeburth; Ottavio Alfieri; Antonio Colombo; Giovanni La Canna; Eustachio Agricola; Michel Zuber; Felix C Tanner; Yan Topilsky; Felix Kreidel; Karl-Heinz Kuck
Journal:  Eur Heart J       Date:  2015-11-18       Impact factor: 29.983

10.  High body mass index is a risk factor for difficult deep sedation in percutaneous mitral valve repair.

Authors:  Katharina Hellhammer; Shazia Afzal; Renate Tigges; Maximilian Spieker; Tienush Rassaf; Tobias Zeus; Ralf Westenfeld; Malte Kelm; Patrick Horn
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

View more
  1 in total

1.  Mitral valve leaflet repair with the new PASCAL system: early real-world data from a German multicentre experience.

Authors:  Steffen D Kriechbaum; Niklas F Boeder; Luise Gaede; Martin Arnold; Ursula Vigelius-Rauch; Peter Roth; Michael Sander; Andreas Böning; Matthias Bayer; Albrecht Elsässer; Helge Möllmann; Christian W Hamm; Holger M Nef
Journal:  Clin Res Cardiol       Date:  2019-08-26       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.